PHARMACOGENETICS AND PHARMACOGENOMICS

Pharmacology and Therapeutics: Principles to Practice

Volumn , Issue , 2008, Pages 219-224

  Weinshilboum, Richard ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84936781534     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3291-5.50019-6     Document Type: Chapter

References (48)

1. RM Weinshilboum and L Wang (2006) Pharmacogenetics and pharmacogenomics: development, science, and translation. Annu Rev Genomics Hum Genet 7 223-245.
2. W Kalow (1962) Pharmacogenetics: Heredity and the Response to Drugs Philadelphia, London: WB Saunders
3. RM Weinshilboum (1987) The therapeutic revolution. Clin Pharmacol Ther 42 481-484.
4. ES Lander, LM Linton, B Birren, et al. (2001) Initial sequencing and analysis of the human genome. Nature 409 860-921.
5. Nature 411 720. [published errata appears in: 412: 565]
6. JC Venter, MD Adams, EW Myers, et al. (2001) The sequence of the human genome. Science 291 1304-1351.
7. Science 292 1838. [published errata appears in:]
8. MJ Rieder, AP Reiner, BF Gage, et al. (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352 2285-2293.
9. EA Sconce, TI Khan, HA Wynne, et al. (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106 2329-2333.
10. M Wadelius, LY Chen, K Downes, et al. (2005) Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 5 262-270.
11. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health. “Draft” Guidance for Industry: Pharmacogenomics Data Submissions. In November 2003.
12. CR Scriver and B Childs (1989) Garrod's Inborn Factors in Disease New York: Oxford University Press
13. W Kalow and DR Gunn (1957) The relationship between dose of succinylcholine and duration of apnea in man. J Pharmacol Exp Ther 120 203-214.
14. DA Price Evans, KA Manley and VA McKusick (1960) Genetic control of isoniazid metabolism in man. Br Med J 2 485-491.
15. WW Weber (1987) The Acetylator Genes and Drug Response New York: Oxford University Press
16. MM Reidenberg, DE Drayer, M Levy and H Warner (1975) Polymorphic acetylation of procainamide in man. Clin Pharmacol Ther 17 722-730.
17. JA Timbrell, SJ Harland and V Facchini (1980) Polymorphic acetylation of hydralazine. Clin Pharmacol Ther 28 350-355.
18. HM Perry Jr, EM Tan, S Carmody and A Sakamoto (1970) Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine. J Lab Clin Med 76 114-125.
19. RL Woosley, DE Drayer, MM Reidenberg, et al. (1978) Effect of acetylator phenotype on the rate at which procainamide induces antinuclear and the lupus syndrome. N Engl J Med 298 1157-1159.
20. MA Belfort, J Anthony, GR Saade, et al. (2003) A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. N Engl J Med 348 304-311.
21. AL Taylor, S Ziesche, C Yancy, et al. (2004) A-AHFT: combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351 2049-2057.
22. MA Branca (2005) BiDil raises questions about race as a marker. Nat Rev Drug Discov 4 615-616.
23. ES Vesell and JG Page (1968) Genetic control of drug levels in man: antipyrine. Science 161 72-73.
24. A Mahgoub, JR Idle, LG Dring, et al. (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2 584-586.
25. L Bertilsson, YQ Lou, YL Du, et al. (1992) Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 51 388-397.
26. Clin Pharmacol Ther 55 648. [published erratum appears in: ].
27. I Johansson, E Lundqvist, L Bertilsson, et al. (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A 90 11825-11829.
28. HK Kroemer and M Eichelbaum (1995) “It's the genes, stupid.” Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 56 2285-2298.
29. O Mortimer, K Persson, MG Ladona, et al. (1990) Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: relationship to the presence of immunoidentified cytochrome P-450IID1. Clin Pharmacol Ther 47 27-35.
30. SH Sindrup and K Brosen (1995) The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics 5 335-346.
31. Y Gasche, Y Daali, M Fathi, et al. (2004) Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 351 2827-2831.
32. MP Goetz, SK Knox, VJ Suman, et al. (2007) The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101 113-121.
33. E Aklillu, I Persson, L Bertilsson, et al. (1996) Frequent distribution of ultrarapid metabolizers of debrisoquine in the Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 278 441-446.
34. L Wang and RM Weinshilboum (2006) Thiopurine S-methyltransferase (TPMT) pharmacogenetics: insights, challenges and future directions. Oncogene Rev 25 1629-1938.
35. L Lennard (1992) The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 43 329-339.
36. C Szumlanski, D Otterness, C Her, et al. (1996) Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 15 17-30.
37. H-L Tai, EY Krynetski, CR Yates, et al. (1996) Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 58 694-702.
38. ESR Collie-Duguid, SC Pritchard, RH Powrie, et al. (1998) The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 9 37-42.
39. H-L Tai, EY Krynetski, EG Schuetz, et al. (1997) Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT3A, TPMT2): mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci U S A 94 6444-6449.
40. L Wang, W Sullivan, D Toft and R Weinshilboum (2003) Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation. Pharmacogenetics 13 555-564.
41. PJ Bosma, JR Chowdhury, C Bakker, et al. (1995) The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 333 1171-1175.
42. L Iyer, S Das, L Janisch, et al. (2002) UGT1A128 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2 43-47.
43. GP Aithal, CP Day, PJ Kesteven and AK Daly (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353 717-719.
44. T Li, CY Chang, DY Jin, et al. (2004) Identification of the gene for vitamin K epoxide reductase. Nature 427 541-544.
45. S Rost, A Fregin, V Ivaskevicius, et al. (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427 537-541.
46. J Couzin and J Kaiser (2007) Genome-wide association. Closing the net on common disease genes. Science 316 820-822.
47. RF Service (2004) Surviving the blockbuster syndrome. Science 303 1796-1799.
48. RM Weinshilboum and SL Sladek (1980) Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32 651-662.